Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Clin Cancer Res
2014 Feb 15;204:985-94. doi: 10.1158/1078-0432.CCR-13-1999.
Show Gene links
Show Anatomy links
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).
Nies AT
,
Schaeffeler E
,
van der Kuip H
,
Cascorbi I
,
Bruhn O
,
Kneba M
,
Pott C
,
Hofmann U
,
Volk C
,
Hu S
,
Baker SD
,
Sparreboom A
,
Ruth P
,
Koepsell H
,
Schwab M
.
???displayArticle.abstract???
In addition to mutated BCR-ABL1 kinase, the organic cation transporter 1 (OCT1, encoded by SLC22A1) has been considered to contribute to imatinib resistance in patients with chronic myeloid leukemia (CML). As data are conflicting as to whether OCT1 transports imatinib and may serve as a clinical biomarker, we used a combination of different approaches including animal experiments to elucidate comprehensively the impact of OCT1 on cellular imatinib uptake. Transport of imatinib was studied using OCT1-expressing Xenopus oocytes, mammalian cell lines (HEK293, MDCK, V79) stably expressing OCT1, human leukemic cells, and Oct1-knockout mice. OCT1 mRNA and protein expression were analyzed in leukemic cells from patients with imatinib-naïve CML as well as in cell lines. Transport and inhibition studies showed that overexpression of functional OCT1 protein in Xenopus oocytes or mammalian cell lines did not lead to an increased cellular accumulation of imatinib. The CML cell lines (K562, Meg-01, LAMA84) and leukemic cells from patients expressed neither OCT1 mRNA nor protein as demonstrated by immunoblotting and immunofluorescence microscopy, yet they showed a considerable imatinib uptake. Oct1 deficiency in mice had no influence on plasma and hepatic imatinib concentrations. These data clearly demonstrate that cellular uptake of imatinib is independent of OCT1, and therefore OCT1 is apparently not a valid biomarker for imatinib resistance.
Bazeos,
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
2010, Pubmed
Bazeos,
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
2010,
Pubmed
Buchdunger,
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
1996,
Pubmed
Burger,
Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?
2013,
Pubmed
Dohse,
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
2010,
Pubmed
Druker,
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
2001,
Pubmed
Druker,
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
2006,
Pubmed
Druker,
Translation of the Philadelphia chromosome into therapy for CML.
2008,
Pubmed
Eechoute,
Drug transporters and imatinib treatment: implications for clinical practice.
2011,
Pubmed
Fendt,
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.
2013,
Pubmed
Giannoudis,
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.
2013,
Pubmed
Goldman,
How I treat chronic myeloid leukemia in the imatinib era.
2007,
Pubmed
Hu,
Interaction of imatinib with human organic ion carriers.
2008,
Pubmed
,
Xenbase
Hu,
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
2011,
Pubmed
Jonker,
Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations.
2003,
Pubmed
Jonker,
Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene.
2001,
Pubmed
Kell,
Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only.
2011,
Pubmed
Koepsell,
Organic cation transporters.
2003,
Pubmed
Kooijmans,
The involvement of a Na⁺- and Cl⁻-dependent transporter in the brain uptake of amantadine and rimantadine.
2012,
Pubmed
Lips,
Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium.
2005,
Pubmed
,
Xenbase
Lozzio,
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.
1975,
Pubmed
Manley,
The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588.
2013,
Pubmed
Marin,
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
2012,
Pubmed
McWeeney,
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.
2010,
Pubmed
Nies,
Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).
2008,
Pubmed
Nies,
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
2009,
Pubmed
Nies,
Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy.
2011,
Pubmed
Nies,
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).
2011,
Pubmed
O'Brien,
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
2003,
Pubmed
O'Hare,
Pushing the limits of targeted therapy in chronic myeloid leukaemia.
2012,
Pubmed
Ogura,
Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome.
1985,
Pubmed
Oostendorp,
The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.
2009,
Pubmed
Peng,
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
2004,
Pubmed
Quintás-Cardama,
Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
2009,
Pubmed
Rius,
Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.
2003,
Pubmed
Seigneurin,
Human chronic myeloid leukemic cell line with positive Philadelphia chromosome exhibits megakaryocytic and erythroid characteristics.
1987,
Pubmed
Shtivelman,
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.
,
Pubmed
Shu,
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.
2007,
Pubmed
Skorta,
Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
2009,
Pubmed
Sprowl,
Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.
2013,
Pubmed
Thomas,
Active transport of imatinib into and out of cells: implications for drug resistance.
2004,
Pubmed
Tweedie,
Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium.
2013,
Pubmed
Wang,
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.
2002,
Pubmed
Wang,
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.
2008,
Pubmed
White,
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.
2006,
Pubmed
White,
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.
2007,
Pubmed
White,
Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response.
2012,
Pubmed
